They are HER2 + Breast Cancer with 50% exposure, alpha-1 antitrypsin deficiency (dAATD) with 27% exposure, and kidney transplant rejection with 60% exposure [14]. This evidence concerns the gene ERBB2 and Alpha-1-antitrypsin deficiency.